Clinical Impact of 123I-Ioflupane SPECT (DaTscan) in a Movement Disorder Center.
The clinical diagnosis of degenerative forms of parkinsonism is imperfect, with past studies reporting a high rate of misdiagnosis by neurologists and movement disorder specialists, particularly early in the disease course. 123I-ioflupane SPECT (DaTscan) is a diagnostic neuroimaging tool used to distinguish essential tremor from tremor due to degenerative parkinsonisms. The present study expands upon prior studies of the clinical impact of DaTscan imaging in movement disorder centers by assessing quantitative estimates of diagnostic certainty, the impact on subsequent clinical decisions, and the degree to which the asymmetry in the results corresponds to laterality by clinical history and examination.



In a prospective, observational study of the impact of DaTscan imaging in a movement disorder center over the course of 18 months, 4 specialists completed a questionnaire at the time they ordered imaging and again within 1 month after imaging.



Twenty-seven patients underwent DaTscan imaging; the result was normal in 4 cases (14.8%), abnormal in 22 cases (81.4%), and equivocal in 1 case (3.7%). In all cases of a normal result, the post-scan-predicted chance of degenerative parkinsonism decreased compared to the pre-scan prediction (p < 0.05), and in all cases of abnormal scan, the post-scan chance of degenerative parkinsonism increased or remained high (p < 0.0001). Clinical impacts were observed following imaging in a total of 24 patients (88.9%), including changes in medications for 18 patients and psychological impacts for 11 patients. Asymmetric clinical symptoms were corroborated based on the expected asymmetry of dopamine uptake deficits in 57.1% of the cases, were not present in 23.8%, and were opposite of expectations in 19.0% of the scans.



DaTscan imaging results have an impact on physician's confidence in the diagnosis of parkinsonism and may also have a psychological impact on patients. DaTscan imaging may be a useful adjunct to clinical history and examination in selected patients.
Parkinson's Disease and Movement Disorders Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass., USA.
Allison K
AK
Graebner
Daniel
D
Tarsy
Ludy C
LC
Shih
Veronique
V
Vanderhorst
Omesh
O
Kulkarni
Scott
S
Kaplan
David K
DK
Simon
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001921:Brain / Q000000981:diagnostic imaging*; D000066491:Clinical Decision-Making; D003937:Diagnosis, Differential; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009069:Movement Disorders / Q000000981:diagnostic imaging* / Q000628:therapy; D059906:Neuroimaging; D009662:Nortropanes; D020734:Parkinsonian Disorders / Q000000981:diagnostic imaging* / Q000628:therapy; D019275:Radiopharmaceuticals; D062606:Tertiary Care Centers; D015899:Tomography, Emission-Computed, Single-Photon; D055815:Young Adult
D009662:Nortropanes; D019275:Radiopharmaceuticals; C519528:ioflupane